Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback